Copper transport drug restores memory and clears toxic Alzheimer's proteins
Points and comments are a snapshot, not live.
A copper-based drug reduced toxic amyloid-beta and improved memory in Alzheimer's mice.
Monash University researchers tested a copper compound on APP/PS1 mice, a model of Alzheimer's. Over 56 days, the drug reduced toxic amyloid-beta by 42% and improved spatial learning by nearly 44%. The compound had prior safety evaluation for other diseases, potentially accelerating human trials.
What commenters are saying
Commenters are skeptical, noting that countless amyloid-clearing therapies succeed in mice but fail in humans. Some question the amyloid hypothesis itself, citing fraud and a decades-long record of failure. Others argue any effective treatment is welcome. A few point out the drug hasn't reached human trials yet.